Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Non-Current Assets: 2019-2024

Historic Other Non-Current Assets for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $3.2 million.

  • Nurix Therapeutics' Other Non-Current Assets rose 718.53% to $7.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was $7.4 million, marking a year-over-year increase of 718.53%. This contributed to the annual value of $3.2 million for FY2024, which is 17.37% down from last year.
  • Latest data reveals that Nurix Therapeutics reported Other Non-Current Assets of $3.2 million as of FY2024, which was down 17.37% from $3.8 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Other Non-Current Assets registered a high of $3.8 million during FY2023, and its lowest value of $200,000 during FY2020.
  • In the last 3 years, Nurix Therapeutics' Other Non-Current Assets had a median value of $3.2 million in 2024 and averaged $2.6 million.
  • Per our database at Business Quant, Nurix Therapeutics' Other Non-Current Assets spiked by 1,316.50% in 2021 and then slumped by 68.20% in 2022.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Other Non-Current Assets stood at $200,000 in 2020, then soared by 1,316.50% to $2.8 million in 2021, then tumbled by 68.20% to $901,000 in 2022, then surged by 324.31% to $3.8 million in 2023, then decreased by 17.37% to $3.2 million in 2024.